The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone
(VTD) versus thalidomide/dexamethasone (TD) versus vincristine, BCNU, melphalan…

Background Bortezomib plus melphalan and prednisone (VMP) is significantly better than
melphalan plus prednisone alone for elderly patients with untreated multiple myeloma; …

Background An association between the severity of coronavirus disease 2019 (COVID-19)
and the presence of certain chronic conditions has been suggested. However, unlike …

Metal‐free and asymmetric: The first enantioselective diamination of styrenes simply requires
a chiral hypervalent iodine(III) reagent as an oxidant and bismesylimide as a nitrogen …

Maintenance therapy has become a hot field in myeloma, and it may be particularly relevant
in elderly patients because the major benefit results from the initial therapy. We report the …

The value of minimal residual disease (MRD) in multiple myeloma (MM) has been more
frequently investigated in transplant-eligible patients than in elderly patients. Because an …

Rationale: Fibrocytes are progenitor cells characterized by the simultaneous expression of
mesenchymal, monocyte, and hematopoietic stem cell markers. We previously documented …

Melphalan (M), in combination with prednisone (MP), has been the backbone of new
combinations, including bortezomib plus MP (VMP). However, new alkylator-free schemes, such as …

We report compelling evidence for a" gray" condensate of dipolar excitons, electrically
polarised in a 25 nm wide GaAs quantum well. The condensate is composed by a macroscopic …

Purpose The addition of monoclonal antibodies to chemotherapy has significantly improved
treatment of chronic lymphocytic leukemia (CLL). Based on excellent results with the …